DAVID M. MOTT - 30 Jun 2022 Form 4 Insider Report for Epizyme, Inc.

Role
Director
Signature
/s/John Weidenbruch, attorney-in-fact
Issuer symbol
N/A
Transactions as of
30 Jun 2022
Net transactions value
+$23,749
Form type
4
Filing time
05 Jul 2022, 17:06:31 UTC
Previous filing
21 Jun 2022
Next filing
01 Jul 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EPZM Common Stock, par value $0.0001 Award $23,749 +16,156 +7.8% $1.47 224,488 30 Jun 2022 Direct F1
holding EPZM Common Stock, par value $0.0001 106,959 30 Jun 2022 See Note F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were issued to the Reporting Person pursuant to his election under the Issuer's director compensation program to receive such shares in lieu of cash fees of $23,750 for Board services for the second fiscal quarter of 2022. The shares were issued on the last day of the second fiscal quarter and the number of shares was calculated by dividing the cash fees to be paid for the quarter by the closing price of the Issuer's common stock on the last trading day of the quarter.
F2 The shares are directly held by the David Mott Declaration of Trust dated May 31, 2001 as amended (the "Mott Trust"). The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the Mott Trust shares in which the Reporting Person has no pecuniary interest.